In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on Hims & Hers Health, with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Craig Hettenbach’s rating is based on a combination of factors influencing Hims & Hers Health’s current market position. The recent introduction of menopause and perimenopause treatments has generated significant enthusiasm, reflected in the stock’s 16% surge. However, this excitement is tempered by concerns about the sustainability of core growth and the durability of the company’s weight loss segment.
Despite the impressive stock performance, which has risen 160% year-to-date, Hettenbach notes that future earnings revisions will need to play a crucial role in maintaining this momentum. The upcoming Q3’25 earnings report will be pivotal, as the recent stock strength sets a high benchmark. Additionally, while the company’s expansion into new product categories is promising, it faces competition from several established players, adding a layer of uncertainty to its growth trajectory.
According to TipRanks, Hettenbach is ranked #2857 out of 10041 analysts.